| First episode | % | % of total | Recurrent episode | % | % of total |
---|---|---|---|---|---|---|
Medical costs | Â | Â | Â | Â | Â | Â |
Consultations | 62.6 | 35.8% | Â | 59.6 | 47.3% | Â |
Clinical examination | 39.8 | 22.7% | Â | 36.2 | 28.7% | Â |
Microbiologic tests | 17.6 | 10.1% | Â | 6.7 | 5.3% | Â |
Antibody testing | 12.8 | 7.3% | Â | 6.5 | 5.2% | Â |
Complete blood count | 4.6 | 2.6% | Â | 1.5 | 1.2% | Â |
Urine analysis | 4.6 | 2.6% | Â | 3.2 | 2.5% | Â |
Others | 33.0 | 18.9% | Â | 12.3 | 9.8% | Â |
Total | 175.0 | 100% | 58.3% | 126.0 | 100% | 38.8% |
Drug treatment | Â | Â | Â | Â | Â | Â |
Antiviral treatment | 64.0 | 100% | Â | 131.0 | 100% | Â |
Total | 64.0 | 100% | 21.3% | 131.0 | 100% | 40.3% |
Hospital | Â | Â | Â | Â | Â | Â |
Hospitalization | 1.0 | Â | 0.4% | 8.0 | Â | 2.4% |
Total direct costs | 240.0 | Â | 80.0% | 265.0 | Â | 81.5% |
Indirect costs | Â | Â | Â | Â | Â | Â |
Production losses | 60.0 | Â | 20.0% | 60.0 | Â | 18.5% |
Total costs per patient | 300.0 | Â | 100% | 325.0 | Â | 100% |